SCHEMBL24469784

SCHEMBL24469784

CNC(=O)c1ccc(-n2c(=O)c3ccncc3n3ncc(CC4CC4)c23)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 3/20 0.37
ROCK2 O75116 2/20 0.37
PIK3CA P42336 2/20 0.34
USP7 Q93009 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
TNKS O95271 1/20 0.33
TNKS2 Q9H2K2 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
AOC2 O75106 1/20 0.33
RPS6KA3 P51812 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
KDM5A P29375 1/20 0.32
CRBN Q96SW2 2/20 0.32
VCP P55072 1/20 0.32
CDK4 P11802 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24470058 0.96 CDK2 (0.37) CDK2ROCK2PIK3CAUSP7MKNK1
SCHEMBL24469915 0.82 ROCK2 (0.33) ROCK2MKNK1MKNK2TP53MAPT
SCHEMBL24469919 0.82 CDK2 (0.36) CDK2PIK3CAUSP7ALDH1A1CRBN
SCHEMBL24470085 0.81 KDM5A (0.36) PIK3CAUSP7MKNK1MKNK2TP53
SCHEMBL24469782 0.78 HSP90AA1 (0.35) CDK2USP7CRBN
SCHEMBL24469763 0.76 USP7 (0.33) CDK2USP7
SCHEMBL24484055 0.75 USP7 (0.35) CDK2USP7CRBN
SCHEMBL24470063 0.74 MTOR (0.35) CDK2PIK3CAUSP7CRBN
SCHEMBL24469913 0.73 OPRM1 (0.33) CDK2PIK3CAUSP7
SCHEMBL24469996 0.73 EGLN1 (0.40) ALDH1A1LMNACRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
US-11820773-B2 Tricyclic compounds ALIGOS THERAPEUTICS, INC. (US) 2023-11-21 US disclosed
WO-2022115384-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2022-06-02 WO disclosed
US-20220169650-A1 TRICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2022-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220169650-A1 TRICYCLIC COMPOUNDS SLC10A1, PKD1, CEL CDK2 3322/4885ROCK2 3901/4885PIK3CA 2431/4885
US-11820773-B2 Tricyclic compounds SLC10A1, PKD1, CEL CDK2 3322/4885ROCK2 3901/4885PIK3CA 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.